Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Emphasizes Risk Analysis, Labeling Details In Interoperability Draft Guidance

This article was originally published in The Gray Sheet

Executive Summary

For manufacturers designing devices intended to be interoperable with other systems, FDA spelled out its premarket expectations for proper risk analyses, verification and validation studies, and suggested labeling in a Jan. 25 draft guidance.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register